Skin Side Effects from Enhertu
Yes, Enhertu (trastuzumab deruxtecan) causes skin-related adverse effects, with alopecia being the most common (occurring in 37% of patients), followed by rash (8%), pruritus (8%), and skin hyperpigmentation (5-6%). 1
Common Cutaneous Adverse Events
The FDA-approved labeling for Enhertu documents the following skin-related side effects in clinical trials:
Most Frequent (≥5%)
- Alopecia (hair loss): 37% of patients (all grades), with only 0.4% experiencing Grade 3 severity 1
- Rash: 8% of patients, including pustular, maculo-papular, and pruritic variants 1
- Pruritus (itching): 5-8% of patients 1
- Skin hyperpigmentation: 5-6%, including skin discoloration and pigmentation disorders 1
Less Common (<5%)
- Dry eye (6%)
- Other dermatologic manifestations documented in post-marketing surveillance
Severity and Clinical Impact
The vast majority of skin reactions with Enhertu are mild to moderate (Grade 1-2) and do not require treatment discontinuation. In the DESTINY-Breast03 trial, only 0.4% of patients experienced Grade 3-4 alopecia (though per CTCAE v5.0, the maximum grade for alopecia is Grade 2), and severe skin reactions were rare 1.
Importantly, skin toxicities with Enhertu differ substantially from EGFR inhibitors, which commonly cause acneiform rash in seborrheic areas. Enhertu's skin effects are more consistent with chemotherapy-related toxicities given its topoisomerase I inhibitor payload.
Rare but Serious Cutaneous Events
Recent pharmacovigilance data from the FDA Adverse Event Reporting System identified potential safety signals for severe reactions, though these remain uncommon 2:
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN) overlap
- Bullous dermatitis
- Generalized exfoliative dermatitis
One case report documented dermatomyositis developing 7 days after the first Enhertu cycle, suggesting potential immune-mediated mechanisms 3. This patient developed typical dermatomyositis symptoms with proximal muscle weakness that worsened with continued treatment and was poorly controlled despite glucocorticoids and hydroxychloroquine.
Time Course
Cutaneous adverse events with Enhertu typically occur early, with a median time-to-onset of 15 days, and trastuzumab deruxtecan demonstrating the shortest latency among antibody-drug conjugates 2. This early onset pattern necessitates vigilant monitoring during the first treatment cycles.
Management Approach
For routine skin toxicities:
- Alopecia: Patient counseling and supportive care; does not require dose modification
- Mild rash/pruritus: Topical emollients, antihistamines, and mild-to-moderate potency topical corticosteroids 4
- Moderate symptoms: Continue treatment with close monitoring; consider dermatology referral if not improving
For severe reactions (Grade 3-4):
- Immediately discontinue Enhertu for any bullous or exfoliative skin rash 5
- Urgent dermatology consultation
- Consider systemic corticosteroids (0.5-1 mg/kg prednisolone) 4
- Hospitalization may be required for SJS/TEN or DRESS syndrome
Clinical Pitfalls
Do not confuse Enhertu's skin toxicity profile with EGFR inhibitor-related acneiform rash. EGFR inhibitors cause seborrheic distribution rash in >50% of patients, whereas Enhertu's primary cutaneous manifestation is alopecia 5, 6.
The occurrence of skin reactions does not predict treatment efficacy with Enhertu, unlike checkpoint inhibitors where cutaneous immune-related adverse events may correlate with tumor response 7.
Risk Factors
Pharmacovigilance data suggest:
- Elderly patients may be more susceptible to cutaneous adverse events 2
- Male patients showed higher reporting rates 2
- Median time-to-onset of 15 days requires early surveillance 2
Monitoring Recommendations
- Baseline skin assessment before treatment initiation
- Weekly evaluation during the first 6 weeks, then monthly 6
- Patient education on early recognition of severe reactions (blistering, mucosal involvement, facial edema)
- Immediate reporting instructions for concerning symptoms
The overall skin toxicity profile of Enhertu is manageable and rarely requires permanent discontinuation, with alopecia being the predominant concern for most patients.